#Singapore #Emerald Clinical Trials #Glenn Kerkhof #Mary Gunn

Emerald Clinical Trials Confirms Leadership Transition

Emerald Clinical Trials, a prominent player in the global clinical research arena, made headlines on July 30, 2025, when it announced a significant leadership change. Mary Gunn, the recently serving CEO, has stepped down from her position, and the Board of Directors has appointed Glenn Kerkhof as the Interim CEO.

Glenn Kerkhof is not a stranger to the organization; he has been a valuable member of the Board and possesses extensive experience in the clinical research sector. His role will focus on facilitating a smooth transition and ensuring that the organization maintains its operational momentum and continues to meet the expectations of its clients. The Board has initiated the process to find a permanent CEO, emphasizing the necessity for continuity and stability during this period of change.

Sean Carney, Chair of the Board, expressed gratitude towards Mary Gunn for her contributions, stating, "Emerald Clinical Trials is a leading CRO with global capabilities. With Glenn stepping in as Interim CEO, we feel assured in our ability to maintain momentum and deliver for our clients." This transition comes at a crucial time as the company strives to enhance its service offerings and retain its competitive edge in the clinical trials space.

Glenn Kerkhof brings over 30 years of executive experience in clinical research and pharmaceutical services to his new role. Before this appointment, he was the CEO of Chiltern, successfully navigating the company through a phase of international expansion. Additionally, he served as Executive Chairman of George Clinical (now Emerald Clinical Trials), playing a pivotal role in its growth throughout Asia.

In addressing the team and stakeholders, Glenn shared his commitment to ensuring that customers receive outstanding service during this transition. He stated, "Emerald Clinical's strengths lie in our therapeutic focus, scientific depth, and close client partnerships. I am focused on a smooth transition, strong delivery for customers, and supporting our global teams. I am committed to building on our momentum and leading with clarity and purpose."

Emerald Clinical Trials is recognized for its comprehensive trial services and has partnered with over 100 biotech companies and six of the top ten pharmaceutical firms worldwide. Their headquarters is in Singapore, where they leverage operational expertise and scientific excellence to provide clients with extensive clinical trial services across all phases.

The organization is dedicated to maintaining its reputation as a leader in clinical research and meeting the needs of its global client base. As Kerkhof takes the helm, all eyes will be on how he navigates the company through this transitional phase and what strategies will be implemented to further bolster Emerald's standing in the industry.

In conclusion, this leadership change at Emerald Clinical Trials signals a new chapter in its operations and strategic direction. With Glenn Kerkhof stepping in as the Interim CEO, the company aims to ensure that its legacy of delivering quality and success in clinical research continues unabated. Stakeholders eagerly await the announcement of a permanent CEO and any subsequent plans that will shape the future of Emerald Clinical Trials in the competitive healthcare landscape.